Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review.

Zhou, Weimin; Huang, Ji; He, Qiuming; Luo, Qingfeng; Zhang, Xiaofang; Tao, Xuewei; Dong, Hanzhi; Tu, Xinhua

Zhou, Weimin; Huang, Ji; He, Qiuming; Luo, Qingfeng; Zhang, Xiaofang; Tao, Xuewei; Dong, Hanzhi; Tu, Xinhua.

Affiliation

Zhou W; Department of Urology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
Huang J; Department of Urology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
He Q; Department of Urology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
Luo Q; Department of Pathology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
Zhang X; Department of Pathology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
Tao X; Department of Radiology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
Dong H; Department of Internal Medical Oncology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.
Tu X; Department of Urology, Jiangxi Cancer Hospital of Nanchang University, Jiangxi Cancer Center, Nanchang, China.

Front Oncol ; 11: 764352, 2021.

Article in En | MEDLINE | ID: mdl-34820330

Key words

collecting duct carcinoma; immune checkpoint inhibitor; immunotherapy; kidney cancer; targeted therapy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Front Oncol Year: 2021 Document type: Article Affiliation country: China Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google